These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Angiotensin-Neprilysin Inhibition as a Paradigm for All? Vaduganathan M; Desai AS Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of angiotensin-neprilysin inhibition versus enalapril in patient with heart failure with a reduced ejection fraction. Ferrari L; Sada S; Intern Emerg Med; 2015 Apr; 10(3):369-71. PubMed ID: 25537439 [No Abstract] [Full Text] [Related]
6. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD; J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
8. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696. Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD; Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin Receptor-Neprilysin Inhibition Therapy and Improved Exercise Parameters in Heart Failure with Reduced Ejection Fraction. Schwartzmann P Arq Bras Cardiol; 2020 Nov; 115(5):828-829. PubMed ID: 33295444 [No Abstract] [Full Text] [Related]
11. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837 [TBL] [Abstract][Full Text] [Related]
13. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284 [TBL] [Abstract][Full Text] [Related]
14. PARADIGM-HF--the experts' discussion. Jessup M; Fox KA; Komajda M; McMurray JJ; Packer M N Engl J Med; 2014 Sep; 371(11):e15. PubMed ID: 25184757 [No Abstract] [Full Text] [Related]
15. Angiotensin receptor-neprilysin inhibitor therapy in heart failure: An end that justifies the means. Ambrosy AP; Velazquez EJ Am Heart J; 2018 May; 199():176-177. PubMed ID: 29754658 [No Abstract] [Full Text] [Related]
16. Prospective Comparison of ARNi with ACE-I to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF): paragon of a study or further investigation paramount? Krum H Circulation; 2015 Jan; 131(1):11-2. PubMed ID: 25411157 [No Abstract] [Full Text] [Related]
17. Angiotensin Receptor-Neprilysin Inhibition in Heart Failure With Reduced Ejection Fraction: A Paradigm for All? Konstam MA JACC Heart Fail; 2016 Oct; 4(10):823-825. PubMed ID: 27614938 [No Abstract] [Full Text] [Related]
18. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure. Macdonald PS Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501 [TBL] [Abstract][Full Text] [Related]
19. Combined angiotensin receptor and neprilysin inhibition therapy for heart failure. Lu BN; Davis LE JAAPA; 2018 Jul; 31(7):35-37. PubMed ID: 29957605 [TBL] [Abstract][Full Text] [Related]
20. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. McMurray JJ Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]